Dr. Raje on the Design of the ENDURANCE Trial in Newly Diagnosed Multiple Myeloma | OncLive

Dr. Raje on the Design of the ENDURANCE Trial in Newly Diagnosed Multiple Myeloma

July 14, 2020

Noopur S. Raje, MD, discusses the ​design of the randomized phase 3 E​NDURANCE trial in ​newly diagnosed multiple myeloma.

Noopur S. Raje, MD, professor of medicine at Harvard Medical School and director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the ​design of the randomized phase 3 E​NDURANCE (E1A11) trial in ​newly diagnosed multiple myeloma.

At the 2020 ASCO Virtual Scientific Program, ​findings from the study showed that carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) did not significantly improve progression-free survival compared with bortezomib (Velcade), lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma who were not intended for up-front autologous stem cell transplant. 

​The trial randomized ​patients to receive KRd (n = 545) ​versus VRd (n = 542), says Raje. Notably, these are 2 of the most commonly used induction regimens in this space, Raje concludes.


x